1Wysokinski A, Kowman M, Ktoszewska I. The prevalence of met-abolic syndrome and framingham cardiovascular risk scores inadult inpatients taking antipsychotics-a retrospective medical re-cords review[J]. Psychiatr Danub, 2012,24(3):314-22.
2Kagal UA, Torgal SS, Patil NM,et al. Prevalence of the metabol-ic syndrome in schizophrenic patients receiving second-genera-tion antipsychotic agents-a cross-sectional study[J]. J PharmPract, 2012,25(3):368-73.
3Kozumplik 0,Uzun S, Jakovljevic M. Metabolic syndrome in pa-tients with psychotic disorders: diagnostic issues, comorbidityand side effects of antipsychotics[J]. Psychiatr Danub, 2010,22(1):69-74.
4Shanker J, Rao VS, Ravindran V,et al. Relationship of adiponec-tin and leptin to coronary artery disease, classical cardiovascularrisk factors and atherothrombotic biomarkers in the IARS cohort[J]. Thromb Haemost, 2012,108(4):769-80.
5Cohn TA, Remington G, Zipursky RB ,et al. Insulin resistanceand adiponectin levels in drug-free patients with schizophrenia:A preliminary report[J].Can J Psychiatry, 2006, 51(6):382-386.
6Beumer W, Drexhage RC, De Wit H, et al. Increased level of se-rum cytokines, chemokines and adipokines in patients withschizophrenia is associated with disease and metabolic syndrome[J]. Psychoneuroendocrinology, 2012 , 26 [Epub ahead of print].
7Wampers M, Hanssens L, van Winkel R, et al. Differential ef-fects of olanzapine and risperidone on plasma adiponectin levelsover time: Results from a 3-month prospective open-label study[J]. European Neuropsychophannacology. 2012,22(1):17-26.
8Sugai T, Suzuki Y,Fukui N, et al. Dysregulation of adipocyto-kines related to second-generation antipsychotics in normal fast-ing glucose patients with schizophrenia[J]. J Clin Psychopharma-col, 2012,32(3):390-393.
9Hasnain M, Fredrickson SK, Vieweg WV, et al. Metabolic syn-drome associated with schizophrenia and atypical antipsychotics[J]. Curr Diab Rep, 2010,10(3):209-216.
10Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, andmetabolic syndrome in non-Euro-American societies[J]. ClinNeuropharmacol, 2012,35(3):141-147.
2Bernstein J G.Induction of obesity by psychotropic drugs[J].Ann N Y Acad Sci,1987,499 (4):203-215.
3Umbricht D S,Pollack S,Kane J M.Clozapine and weight gain[J].J Clin Psychiatry,1994,55(3):157-160.
4Melkersson K.Clozapine and olanzapine,but not conventional antipsychotics,increase insulin release in vitro[J].Eur Neuropsychopharmacol,2004,14(2):115-119.
5Citrome I L.The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents[J].Drugs Today,2004,40(2):445-464.
6Reynolds G P,Zhang Z J,Zhang X B.Association of antipsychotic drug induced weight gain with a 5-HT2C receptor gene polymorphism[J].Lancet,2002,359(5):2086-2087.
7Yuan X,Yamada K,Ishiyama-Shigemoto S,et al.Identification of polymorphic loci in the promoter region of the serotonin 5HT2C receptor gene and their association with obesity and type 2 diabetes[J].Diabetologia,2000,43(6):373-376.
8Richards A A,Hickman I J,Wang A Y,et al.Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum:a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia[J].J Clin Psycho-pharmacol,2006,26(3):232-237.
9Menzaghi C,Ercolino T,Paola R D,et al.A haplotype at the adiponectin locus is assoclated with obesity and other features of the insulin resistance syndrome[J].Diabetes,2002,57(7):2306.
10American Psychiatric Association.Diagnostic and statistical manual of mental disorders[M].4th ed.Washington DC:APA,1994.
9Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：341
